| 石佳鹏,汤小星,赵辉.程序性死亡受体-1免疫抑制剂在中晚期肝细胞癌中的研究进展[J].中国医药导报,2024,21(1):60-63 |
二维码（扫一下试试看！） |
| 程序性死亡受体-1免疫抑制剂在中晚期肝细胞癌中的研究进展 |
| Research progress of programmed death receptor-1 immunosuppressants in advanced hepatocellular cancer |
| 收稿日期：2023-03-24 |
| DOI：10.20047/j.issn1673-7210.2024.01.12 |
| 关键词: 肝细胞癌 免疫抑制剂 程序性死亡受体-1 预后 |
| Key Words: |
| 基金项目:江苏省自然科学基金青年基金项目（BK20190177） |
|
| 摘要点击次数: 396 |
| 全文下载次数: 394 |
| 摘要:肝细胞癌（HCC）是肝癌中最为常见的一种，中晚期HCC预后差，其发病率在许多国家呈上升趋势。近年来，随着对HCC免疫及病理机制的深入认识，基于肿瘤免疫微环境调控的免疫治疗成为HCC患者治疗的新选择。以程序性死亡受体-1（PD-1）及其配体程序性死亡受体配体1（PD-L1）为靶点的免疫检查点抑制剂使用最广泛，但是其疗效及安全性还需要更多的临床研究证实，并根据患者的个体情况进行综合评估和选择适当的治疗方案。本文以PD-1为代表，就HCC中PD-1/PD-L1治疗的研究现状，联合经导管动脉化疗栓塞术、酪氨酸激酶抑制剂、局部消融治疗指征，疗效及研究进展等进行综述，为临床治疗HCC及PD-1/PD-L1的后续研究提供依据。 |
| Abstract:Hepatocellular cancer (HCC) is the most common type of liver cancer. The prognosis of HCC in the middle and late stages is poor, and its incidence rate is on the rise in many countries. In recent years, with a deeper understanding of the immune and pathological mechanisms of HCC, immunotherapy based on tumor immune microenvironment regulation has become a new choice for the treatment of HCC patients. Immune checkpoint inhibitors targeting programmed death-1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1) are the most widely used, but their efficacy and safety require further clinical research to confirm, and comprehensive evaluation and selection of appropriate treatment plans based on individual patient conditions are needed. This article reviews the research status of PD-1/PD-L1 therapy in HCC, treatment indications for combined transcatheter arterial chemoembolization, tyrosine kinase inhibitors, and local ablation, efficacy and research progress represented by PD-1. It provides a basis for subsequent research on clinical treatment of HCC and PD-1/PD-L1. |
| 查看全文 HTML 查看/发表评论 下载PDF阅读器 |
